Andrew Berens
Stock Analyst at Leerink Partners
(0.98)
# 3,518
Out of 4,831 analysts
123
Total ratings
43.9%
Success rate
-14.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $1.97 | +205.34% | 3 | Apr 2, 2025 | |
| AGIO Agios Pharmaceuticals | Downgrades: Market Perform | $60 → $56 | $28.52 | +96.35% | 11 | Sep 27, 2024 | |
| CELC Celcuity | Initiates: Outperform | $29 | $10.74 | +170.14% | 1 | Jul 22, 2024 | |
| BPMC Blueprint Medicines | Upgrades: Market Perform | $50 → $97 | $99.70 | -2.71% | 24 | May 6, 2024 | |
| COGT Cogent Biosciences | Maintains: Outperform | $18 → $20 | $4.96 | +303.23% | 4 | Jan 5, 2023 | |
| ARVN Arvinas | Maintains: Outperform | $74 → $70 | $6.23 | +1,023.60% | 5 | Nov 23, 2022 | |
| AZN AstraZeneca | Maintains: Outperform | $78 → $79 | $67.71 | +16.68% | 12 | Nov 14, 2022 | |
| CGEM Cullinan Therapeutics | Maintains: Outperform | $36 → $25 | $7.64 | +227.23% | 3 | May 13, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | $40 | $5.28 | +657.58% | 1 | Nov 23, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $67 | $1.48 | +4,427.03% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $1 | $0.35 | +183.29% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $1.80 | +1,733.33% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $10 → $25 | $11.75 | +112.77% | 10 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $101.80 | -5.70% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $69 → $110 | $71.19 | +54.52% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $60.85 | +28.18% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $48 | $41.13 | +16.70% | 5 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $9.81 | +185.42% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $1.23 | +2,095.12% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $1.38 | +2,073.91% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $4.08 | +390.80% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $1.40 | +1,685.71% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $7.04 | +13.64% | 7 | Jul 14, 2017 |
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $1.97
Upside: +205.34%
Agios Pharmaceuticals
Sep 27, 2024
Downgrades: Market Perform
Price Target: $60 → $56
Current: $28.52
Upside: +96.35%
Celcuity
Jul 22, 2024
Initiates: Outperform
Price Target: $29
Current: $10.74
Upside: +170.14%
Blueprint Medicines
May 6, 2024
Upgrades: Market Perform
Price Target: $50 → $97
Current: $99.70
Upside: -2.71%
Cogent Biosciences
Jan 5, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $4.96
Upside: +303.23%
Arvinas
Nov 23, 2022
Maintains: Outperform
Price Target: $74 → $70
Current: $6.23
Upside: +1,023.60%
AstraZeneca
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $67.71
Upside: +16.68%
Cullinan Therapeutics
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $7.64
Upside: +227.23%
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $5.28
Upside: +657.58%
C4 Therapeutics
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $1.48
Upside: +4,427.03%
Mar 21, 2025
Downgrades: Market Perform
Price Target: $9 → $1
Current: $0.35
Upside: +183.29%
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $1.80
Upside: +1,733.33%
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $11.75
Upside: +112.77%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $101.80
Upside: -5.70%
Apr 1, 2024
Upgrades: Outperform
Price Target: $69 → $110
Current: $71.19
Upside: +54.52%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $60.85
Upside: +28.18%
Apr 17, 2023
Maintains: Outperform
Price Target: $35 → $48
Current: $41.13
Upside: +16.70%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $9.81
Upside: +185.42%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $1.23
Upside: +2,095.12%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $1.38
Upside: +2,073.91%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $4.08
Upside: +390.80%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $1.40
Upside: +1,685.71%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $7.04
Upside: +13.64%